Literature DB >> 10188720

Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas.

H Echchakir1, C Asselin-Paturel, G Dorothee, I Vergnon, D Grunenwald, S Chouaib, F Mami-Chouaib.   

Abstract

Non-small-cell lung cancers (NSCLC) are often infiltrated by T lymphocytes. It is postulated that the presence of tumor-infiltrating lymphocytes (TIL) reflects a local host immune response against autologous tumors. To identify the nature of NSCLC TIL, we have characterized the molecular structure of the TCRbeta chain expressed by infiltrating T cells and paired PBL from 9 untreated patients (4 LLC, 3 ADC and 2 SCC). For this purpose, we have used a high-resolution PCR-based method that determines CDR3 size patterns in TCRVbeta sub-families in fresh tumors and their corresponding autologous PBL samples. Oligoclonality in T-cell populations was observed in 3 (Hor, Bla and Pub) out of 9 tumor biopsies analyzed. In contrast, the TCR repertoire of the 6 following patients as well as of all the autologous PBL was diverse, with virtually all Vbeta specificities expressed. Among the 3 tumors with dominant T-cell clonotypes, relative expansion of some T-cell sub-populations was observed. One patient (Hor) with significant TCRVbeta21 expansion in tumor compared with autologous PBL, showed over-expression of a particular TCRVbeta chain with unique Vbeta21-D-Jbeta2.7 junctional region not detected in autologous PBL. TCRVbeta21/Jbeta2.7 expansion was also observed in IL-2-stimulated TIL cell lines and was confirmed by sequencing analysis of the V-D-J junctional region. These results strengthen the view that local antigen-driven selection may occur, and support the hypothesis that anti-tumor immune response may take place in some NSCLC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188720     DOI: 10.1002/(sici)1097-0215(19990412)81:2<205::aid-ijc7>3.0.co;2-m

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy.

Authors:  Minying Zhang; Sourindra Maiti; Chantale Bernatchez; Helen Huls; Brian Rabinovich; Richard E Champlin; Luis M Vence; Patrick Hwu; Laszlo Radvanyi; Laurence J N Cooper
Journal:  Clin Cancer Res       Date:  2012-07-03       Impact factor: 12.531

2.  Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.

Authors:  H Pilch; H Höhn; C Neukirch; K Freitag; P G Knapstein; B Tanner; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

3.  Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients.

Authors:  Sebastian Ochsenreither; Alberto Fusi; Susanne Wojtke; Antonia Busse; Natascha C Nüssler; Eckhard Thiel; Ulrich Keilholz; Dirk Nagorsen
Journal:  J Transl Med       Date:  2010-04-12       Impact factor: 5.531

Review 4.  Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

Authors:  Angel Qin; David G Coffey; Edus H Warren; Nithya Ramnath
Journal:  Cancer Med       Date:  2016-07-15       Impact factor: 4.452

Review 5.  Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.

Authors:  Aurélie Durgeau; Yasemin Virk; Stéphanie Corgnac; Fathia Mami-Chouaib
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

6.  Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial.

Authors:  Cunte Chen; Si-Yang Maggie Liu; Yedan Chen; Qiuxiang Ou; Hua Bao; Ling Xu; Yikai Zhang; Wenzhao Zhong; Qing Zhou; Xue-Ning Yang; Yang Shao; Yi-Long Wu; Si-Yang Liu; Yangqiu Li
Journal:  JCI Insight       Date:  2022-01-11

7.  Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Authors:  Grégoire Wieërs; Nathalie Demotte; Danièle Godelaine; Pierre Van der Bruggen
Journal:  Cancers (Basel)       Date:  2011-07-18       Impact factor: 6.639

8.  Differences in TCR-Vβ repertoire and effector phenotype between tumor infiltrating lymphocytes and peripheral blood lymphocytes increase with age.

Authors:  Hongwei Shao; Yusheng Ou; Teng Wang; Han Shen; Fenglin Wu; Wenfeng Zhang; Changli Tao; Yin Yuan; Huaben Bo; Hui Wang; Shulin Huang
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

Review 9.  The Treg/Th17 paradigm in lung cancer.

Authors:  Min-Chao Duan; Xiao-Ning Zhong; Guang-Nan Liu; Jin-Ru Wei
Journal:  J Immunol Res       Date:  2014-04-29       Impact factor: 4.818

Review 10.  T Cell Receptor Profiling in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Amanda Posgai; Howard R Seay; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2017-10-11       Impact factor: 4.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.